Compare Albemarle Corp. (ALB) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albemarle Corp. vs Amphastar Pharmaceuticals Inc — how do they compare? Albemarle Corp. trades at $129.79 (market cap $15.48B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Albemarle Corp. is far larger — about 17.9× Amphastar Pharmaceuticals Inc's market cap, and Albemarle Corp. pays a 1.25% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| ALB | AMPH | |
|---|---|---|
Market Cap | $15.48B | $863.95M |
Sector | Basic Materials | Health |
52-Week High | $215.62 | $30.81 |
52-Week Low | $72.58 | $16.87 |
Enterprise Value | $17.96B | $1.26B |
Dividend Yield | 1.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albemarle (ALB) trades at $131.11, up 4.54% today, with a bullish technical signal and strong Q2 2026 earnings beating estimates. The stock shows improved cash flow and lithium demand strength, though valuation metrics like a P/E of 485.59 indicate high expectations. Recent news highlights earnings growth and dividend stability, with support at $127 and resistance at $134.
Outlook is cautiously optimistic with analyst consensus target of $184.50, but risks include volatile lithium prices and high valuation. Investment opportunity lies in sustained demand for energy storage, balanced by margin pressures and debt levels.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Albemarle Corp.
Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.
Read more on ALB →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
